To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Introduction: The National Institute of Clinical Excellence (NICE) currently recommends using the 21-gene Oncotype DX assay to help guide decisions about chemotherapy (CT) after surgery in some patients with lymph node negative early breast cancer.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile